Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities

Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities

ABSTRACT Monoclonal antibodies (mAbs) are critical components in the therapeutic landscape, but their dosing strategies often evolve post‐approval as new data emerge. This review evaluates post‐marketing label changes in dosing information for FDA‐approved mAbs from January 2015 to September 2024, w...

Full description

Saved in:
Bibliographic Details
Main Authors: Nai Lee, Su‐jin Rhee, Seong Min Koo, So Won Kim, Gyo Eun Lee, Yoon A Yie, Yun Kim
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Clinical and Translational Science
Subjects:
drug information
drug safety
drug utilization
monoclonal antibodies
pharmacovigilance
Online Access:https://doi.org/10.1111/cts.70125
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70125

Similar Items